This blog was originally posted on Devex. An estimated 400 million people do not have access to basic health care services. That’s about 1 in every 16 people who cannot visit a hospital or clinic to have their blood pressure measured, or learn how to properly care for their child with diabetes. Universal health coverage...
Read moreA must-watch: Dr Manisha A. Desai, assistant general patent counsel at Eli Lilly and Company, gives her take on the importance of the Convention of Biodiversity and the Nagoya Protocol for the pharma industry. What’s key is to increase the awareness of the potential impacts of the Nagoya Protocol on research and on our ability...
Read moreThe driving motivation of the pharmaceutical industry is to improve human health and well-being. Climate change will challenge the global community in its efforts to tackle health concerns and inequalities across the world. It can have consequences both for people living today, especially the poorest and most vulnerable, and for future generations. It is...
Read moreHave a quick look at our ‘pharma by numbers’ video illustrating the key 2015 facts & figures that range from innovation in R&D, to pharma & global health, and the pharma economic footprint. This video is based on the IFPMA yearly flagship publication http://ifpma.org
Read moreFPMA believes it is imperative to underscore the importance of NCDs as a key component of sustainable development, by revisiting its Framework to ensure it is relevant and applicable in the post-2015 agenda.
Read more